NEJM Paper Yields Positive Efficacy Results for Roche/Plexxikon's PGx Melanoma Drug

Although the study published in NEJM showed that 81 percent of melanoma patients responded to PLX4032, some questions remain about how and why patients are developing resistance to the therapy, and whether the drug improves overall survival.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.